Published in Ann Neurol on January 01, 2000
Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest (2002) 2.48
Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev (2008) 2.27
Neurological channelopathies. Postgrad Med J (2005) 1.98
Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness. J Clin Invest (2008) 1.03
Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med (2008) 1.01
Channelopathies of skeletal muscle excitability. Compr Physiol (2015) 0.94
Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology (2011) 0.93
Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats. Br J Pharmacol (2008) 0.93
Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol (2012) 0.88
Treatment of neuromuscular channelopathies: current concepts and future prospects. Neurotherapeutics (2008) 0.86
Genetic neurological channelopathies: molecular genetics and clinical phenotypes. J Neurol Neurosurg Psychiatry (2015) 0.85
Familial Episodic Ataxias and Related Ion Channel Disorders. Curr Treat Options Neurol (2000) 0.85
A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G). J Korean Med Sci (2005) 0.84
Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre. Acta Myol (2008) 0.81
Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis. Neurology (2013) 0.80
Skeletal muscle na channel disorders. Front Pharmacol (2011) 0.79
Rare neurological channelopathies - networks to study patients, pathogenesis and treatment. Nat Rev Neurol (2016) 0.78
Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology (2016) 0.78
Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg (1970) 5.62
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 5.36
The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 4.86
Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet (1997) 4.29
Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet (2000) 4.22
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology (1997) 3.68
Insulin-regulatable tissues express a unique insulin-sensitive glucose transport protein. Nature (1988) 3.57
Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44
Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med (1994) 3.42
Nationalism and patriotism: national identification and out-group rejection. Br J Soc Psychol (2001) 3.33
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med (1989) 3.32
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med (1995) 3.28
Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature (1995) 3.22
Inactivation of the N-CAM gene in mice results in size reduction of the olfactory bulb and deficits in spatial learning. Nature (1994) 3.19
Detection of human cytomegalovirus in clinical specimens by DNA-DNA hybridization. J Infect Dis (1984) 3.10
Prevalence of urethral Chlamydia trachomatis and Neisseria gonorrhoeae among asymptomatic, sexually active adolescent boys. J Infect Dis (1987) 3.02
Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet (1996) 3.02
Trauma care regionalization: a process-outcome evaluation. J Trauma (1999) 3.02
11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A (1997) 3.00
A prospective assessment of mortality in chronic spinal cord injury. Spinal Cord (2005) 2.96
Clinical aspects of X-linked hypohidrotic ectodermal dysplasia. Arch Dis Child (1987) 2.95
Reaction of endotoxin and surfactants. I. Physical and biological properties of endotoxin treated with sodium deoxycholate. J Bacteriol (1966) 2.86
Mitochondrial toxicity of antiviral drugs. Nat Med (1995) 2.83
Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol (1994) 2.82
Human immunodeficiency virus infection of human-PBL-SCID mice. Science (1991) 2.77
Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2003) 2.76
Evaluation of readability and accuracy of information leaflets in general practice for patients with asthma. BMJ (1998) 2.75
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
Inclusion body myositis and myopathies. Ann Neurol (1995) 2.68
Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis (1984) 2.67
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 2.67
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Correlating phenotype and genotype in the periodic paralyses. Neurology (2004) 2.55
Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53
Evidence for a polar ethane cloud on Titan. Science (2006) 2.50
Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell (1991) 2.48
A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med (1990) 2.48
Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med (1987) 2.46
The evolution of Titan's mid-latitude clouds. Science (2005) 2.46
Hand-held thoracic sonography for detecting post-traumatic pneumothoraces: the Extended Focused Assessment with Sonography for Trauma (EFAST). J Trauma (2004) 2.44
Human N-ras: cDNA cloning and gene structure. Nucleic Acids Res (1985) 2.41
The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature (1987) 2.38
Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry (1988) 2.36
Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet (1993) 2.35
An evaluation of the Gaspak system in the culture of anaerobic bacteria. J Appl Bacteriol (1972) 2.33
Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis (1997) 2.31
A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care (1991) 2.30
Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med (1986) 2.22
An acute axonal form of Guillain-Barré polyneuropathy. Brain (1986) 2.20
Symptoms of depression and survival experience among three samples of smokers trying to quit. Psychol Addict Behav (2001) 2.20
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med (1992) 2.19
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet (1998) 2.17
The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain (2005) 2.17
Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology (2002) 2.17
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
A novel cDNA detects homozygous microdeletions in greater than 50% of type I spinal muscular atrophy patients. Nat Genet (1995) 2.17
Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology (1991) 2.16
Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell (1994) 2.15
A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med (1997) 2.15
Intramuscular rocuronium in infants and children. Dose-ranging and tracheal intubating conditions. Anesthesiology (1996) 2.14
Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry (1984) 2.14
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis (1997) 2.14
Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa. J Clin Microbiol (2007) 2.12
Cause of death in rheumatoid arthritis. Br J Rheumatol (1984) 2.12
Dysphagia in patients with the post-polio syndrome. N Engl J Med (1991) 2.09
Insuring Latinos against the costs of illness. JAMA (1993) 2.09
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08
Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. J Infect Dis (1990) 2.08
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol (1991) 2.07
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA (2001) 2.06
Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve (1981) 2.06
A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. Anesthesiology (1999) 2.03
Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation (1993) 2.02
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem (1996) 2.01
Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst (1985) 2.00
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA (1998) 2.00
Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve (1983) 1.99
New cosmid vectors developed for eukaryotic DNA cloning. Gene (1984) 1.97
Acute infectious epiglottitis in adults. Ann Intern Med (1969) 1.97
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis (1995) 1.97
Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology (2000) 1.96
Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry (1986) 1.95
Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol Immunol (1989) 1.94
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Training in international animal health. Vet Rec (2001) 1.93
A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis (1993) 1.93
EXPERIENCES WITH SODIUM AMYTAL AS A GENERAL ANAESTHETIC. Ann Surg (1930) 1.93
A death-domain-containing receptor that mediates apoptosis. Nature (1996) 1.92
Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol (2001) 1.91